Original research
Internal Medicine
Original research relevant to this speciality, newest first.
- Apixaban shows the most favourable anticoagulation balance in disabled nursing-home residents with atrial fibrillation
JAMA Network Open
Observational study, 26,940 residents. Anticoagulants were associated with fewer strokes but more major bleeding; apixaban had the most favourable profile among those studied. - Survodutide reduces weight and HbA1c in adults with obesity and type 2 diabetes
NEJM
SYNCHRONIZE-2 phase 3 trial, 752 participants. Weight change at 76 weeks reached −9.8% versus −3.9% with placebo; gastrointestinal adverse events were common. - Retatrutide produces substantial weight loss in adults with obesity without diabetes
NEJM
TRIUMPH-1 phase 3 trial, 2,339 participants. Treatment-regimen estimate at 80 weeks: up to 25.0% weight loss versus 3.9% with placebo. - Retatrutide produces substantial weight loss in adults with obesity and type 2 diabetes
The Lancet
Phase 3, 1,152 participants. At 80 weeks, weight fell 18.8% with 12 mg versus 5.1% with placebo, using the primary treatment-regimen estimand. Gastrointestinal adverse effects were more frequent. - Petrelintide reduces weight in a phase 2 obesity trial
The Lancet Diabetes & Endocrinology
Phase 2. Weight loss up to 9.8% versus 1.7% at the 28-week primary endpoint. No direct comparison with GLP-1 drugs. - Fasting beyond 12 hours adds little to routine laboratory testing
JAMA Internal Medicine
Large cross-sectional analysis. Supports test-specific fasting requirements; it does not mean fasting is unnecessary for every test.